Together, these results provide initial evidence for SHANK3 in PBMCs and plasma beta-synuclein as complementary liquid biomarkers to aid prognosis and enable objective monitoring of therapeutic response in PMS, warranting validation in larger and pediatric longitudinal cohorts. The gene discussed is SNCB; the disease is premenstrual tension.